MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

20th International Congress » Huntington's disease

Date: Wednesday, June 22, 2016

Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Session Type: Poster Session

Meeting: 20th International Congress

12:00pm-1:30pm
A health cost analysis for Huntington disease in Peru

G. Silva-Paredes, M. Cornejo-Olivas, M. Inca-Martinez, K. Espinoza-Huertas, A. Vishnevetsky, P. Mazzetti, R. Urbanos-Garrido (Lima, Peru)

12:00pm-1:30pm
A randomized double-blind placebo- and positive-controlled crossover study to evaluate the effects of single doses of SD-809 (deutetrabenazine) and tetrabenazine on the corrected QT interval

D. Stamler, E. Offman, M. Bradbury, L. De Boer (La Jolla, CA, USA)

12:00pm-1:30pm
Abnormal intrinsic brain activity reveals neural correlates of impaired cognitive function in early stage of Huntington’s disease (HD): A resting-state fMRI study

W. Liu, J. Yang, K. Chen, C. Luo, J.M. Burgunder, Q. Gong, H. Shang (Chengdu, People's Republic of China)

12:00pm-1:30pm
Altered cerebello-thalamo-cortical pathway in Huntington’s disease

J.F. Martín-Rodríguez, M. Gómez-Crespo, M.T. Cáceres-Redondo, L. Vargas-González, F.J. Palomar, P. Porcacchia, P. Álvarez de Toledo, J.M. Oropesa-Ruiz, F. Carrillo, I. Huertas-Fernández, S. Jesús, P. Mir (Seville, Spain)

12:00pm-1:30pm
Alternatives for reducing chorea in Huntington disease, a long-term trial (ARC-HD): Updated week 8 results for the switch cohort

V. Sung, D. Stamler, D.O. Claassen (Birmingham, AL, USA)

12:00pm-1:30pm
Beneficial effect of L-theanine against 3-nitropropionic acid induced neurotoxicity in rats: Possible role of neurotransmitters and nitric oxide

P. Kumar, S. Jamwal (Moga, India)

12:00pm-1:30pm
CAG repeat length and weight loss in pre-manifest Huntington’s disease

C.F. Kutz, L.J. Adams (Colorado Springs, CO, USA)

12:00pm-1:30pm
Cerebellar gray matter alterations in Huntington disease: A voxel-based morphometry study

P. Azevedo, R. Guimarães, L. Piovesana, C. Piccinin, M.C. Arci, L. Villany, L. Campos, G. Pinheiro, J. Zuiane, A. Amato Filho, F. Cendes, Í. Lopes-Cendes, A. D'Abreu (Campinas, Brazil)

12:00pm-1:30pm
Clinical and behavioral features in carriers of intermediate length alleles of HTT gene. A case series of Mexican population

M.A. Ramírez-García, D.J. Dávila-Ortiz de Montellano, P. Yescas-Gómez, A. Ochoa-Morales, C. Boll, M.E. Alonso-Vilatela (Mexico City, Mexico)

12:00pm-1:30pm
Clinical and neuroimaging correlations in early manifest Huntington’s disease patients: Default mode network properties according to resting-state functional MRI

Y.A. Seliverstov, E.V. Seliverstova, S.A. Klyushnikov, R.N. Konovalov, S.N. Illarioshkin (Moscow, Russia)

12:00pm-1:30pm
Clinical presentation and genetic characteristics of Huntingtons disease in Croatia: Thirty years of experience

M. Relja, I. Jurjevic, K. Blazina, V. Miletic, N. Klepac (Zagreb, Croatia)

12:00pm-1:30pm
Cognitive impairment in Huntington’s disease

N. Kamble, N. Netravathi, K. Kumar, S. Jain, P.K. Pal (Bangalore, India)

12:00pm-1:30pm
Communication and language skills in Huntington’s disease

Y. Manor, D. Shpunt, S. Naor, L. Frydman, A. Gad, A. Ezra, A. Migirov, J. Knaani, A. Socher, T. Gurevich (Tel-Aviv, Israel)

12:00pm-1:30pm
Cortico-striatal functional connectivity in the premanifest and manifest period of Huntingtons disease measured with high-field functional magnetic resonance imaging

M. Kronenbuerger, J. Hua, C.A. Ross (Baltimore, MD, USA)

12:00pm-1:30pm
CSF inflammatory and cell death biomarkers in Huntington’s disease – An exploratory cross-sectional study

F.B. Rodrigues, L. Byrne, S.J. Tabrizi, H. Zetterberg, E. Wild (London, United Kingdom)

12:00pm-1:30pm
Dysphagia in early stage Huntington’s disease (HD) – Pilot observations from a multimodal imaging study

I. Trender-Gerhard, E. Michou, A. Gerhard, D. Craufurd, S. Hamdy, K. Herholz (Manchester, United Kingdom)

12:00pm-1:30pm
Dysregulations of GABAergic neurotransmission in Huntington’s disease brain

Y.T. Hsu, Y.G. Chang, H.M. Chen, Y. Chern (Taichung, Taiwan)

12:00pm-1:30pm
Emotional facial EMG responses are affected in Huntington’s disease

C.C. Kordsachia, I. Labuschagne, J. Stout (St. Kilda, Australia)

12:00pm-1:30pm
Enroll-HD: A global clinical research platform for Huntington’s disease

T.A. Mestre, C. Fitzer-Attas, J. Giuliano, B. Landwehrmeyer, C. Sampaio (Ottawa, Canada)

12:00pm-1:30pm
Epidemiology and economic burden of falls and fractures in patients with Huntington’s disease

D.O. Claassen, P. Donga, S. Rajagopalan, L.M. De Boer, B. Carroll, S. Gandhi (Nashville, TN, USA)

12:00pm-1:30pm
Evaluating swallowing function in patients with Huntington disease enrolled in the first-HD study

S.A. Frank, D.O. Claassen, S. Janicki, D. Oakes, D. Stamler, V. Sung, C. Vaughn, C.M. Testa, On behalf of First-HD HSG Investigators (Boston, MA, USA)

12:00pm-1:30pm
Evaluation of quality of life (QOL), patient- and clinician-reported outcomes with deutetrabenazine treatment of chorea in Huntington disease in first-HD

C.M. Testa, D.O. Claassen, D. Oakes, D. Stamler, V. Sung, S. Frank, On behalf of the First-HD HSG Investigators (Richmond, VA, USA)

12:00pm-1:30pm
Fast and simple non-invasive screening tool for mitochondrial changes in Huntington’s disease

P. Dušek, M. Rodinová, I. Lišková, E. Trefilová, Z. Ellederová, J. Klempír, J. Roth, H. Hansíková (Prague, Czech Republic)

12:00pm-1:30pm
Fifteen years of clinical trials in Huntington’s disease: Too many clinical trial failures

A.M. Travessa, F.B. Rodrigues, T.A. Mestre, C. Sampaio, J.J. Ferreira (Lisboa, Portugal)

12:00pm-1:30pm
Huntington disease phenocopies or misdiagnosis: A black South African cohort

F.K. Baine, A. Krause (Johannesburg, South Africa)

12:00pm-1:30pm
Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the FIRST-HD and TETRA-HD trials

D.O. Claassen, B. Carroll, L.M. De Boer, E. Wu, R. Ayyagari, S. Gandhi, D. Stamler (Nashville, TN, USA)

12:00pm-1:30pm
Interleaved pro- and anti-saccade performance in Huntington’s disease

I. Vaca-Palomares, J. Fernandez-Ruiz, B. Coe, D.P. Munoz (Kingston, ON, Canada)

12:00pm-1:30pm
Magnetic resonance imaging and pyramidal impairment in Huntington disease

A. Sanguinetti, S. Lescano, M. Cesarini, J. Etcheverry, E. Gatto (Buenos Aires, Argentina)

12:00pm-1:30pm
Maintenance of balance function in patients with HD treated with deutetrabenazine, as measured by Berg balance test (BBT) in First-HD

D.O. Claassen, D. Oakes, D. Stamler, V. Sung, C.M. Testa, S. Frank, On behalf of the First-HD HSG Investigators (Nashville, TN, USA)

12:00pm-1:30pm
Neurophysiological evidence of posterior-cortical alterations in premanifest Huntington’s: An event-related brain potentials study of face and face-like objects processing

S. Martinez-Horta, J. Perez-Perez, A. Horta-Barba, R. Fernandez-Bobadilla, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

12:00pm-1:30pm
Neuroprotective potential of L-theanine against excitotoxic neuronal death induced by quinolinic acid: Possible neurotransmitters and nitric oxide modulation mechanism

S. Jamwal, P. Kumar (Moga, India)

12:00pm-1:30pm
Predictors of quality of life in Huntington’s disease. A longitudinal observational study

A. Brás, F. Júlio, M. Sousa, F. Blanco, C. Januário (Coimbra, Portugal)

12:00pm-1:30pm
Program evaluation empowerment of people with Huntington’s disease (HD) and their families: Using goal attainment scaling (GAS)

D. Alburquerque, N. Rojas, S. Tapia, P. Reyes, C. Silva, P. Chana-Cuevas (Santiago, Chile)

12:00pm-1:30pm
Psychosis in Huntington’s disease

J. Perez-Perez, S. Martinez-Horta, M. Carceller, J. Pagonabarraga, A. Horta, R. Fernandez-Bobabilla, J. Kulisevsky (Barcelona, Spain)

12:00pm-1:30pm
Specific in-patient’s rehabilitation improves postural and gait instability in Huntington’s disease

L. Brabcová, J. Roth, O. Horácek, M. Kolárová, H. Bozková, J. Rusz, P. Košková, K. Lísalová, F. Jancok, J. Klempír, E. Ruzicka, H. Brozová (Beroun, Czech Republic)

12:00pm-1:30pm
Strategies for a high quality data in an observational longitudinal study: Enroll-HD experience

N. Gonçalves, D. Abreu, R. Lobo, J. Giuliano, T. Mestre, J.J. Ferreira, C. Fitzer-Attas, B. Landwehrmeyer, C. Sampaio (Lisbon, Portugal)

12:00pm-1:30pm
Striatal molecular alterations in Huntington’s disease gene expansion carriers: A systematic review and meta-analysis of PET studies

F. Niccolini, G. Pagano, P. Fusar-Poli, A. Wood, L. Mrzljak, C. Sampaio, M. Politis (London, United Kingdom)

12:00pm-1:30pm
Suicide attempts and Huntington’s disease: Perseveration, not just impulsivity

O.C. Roman, J.G. Stovall, D.O. Claassen (Nashville, TN, USA)

12:00pm-1:30pm
Swallowing disorders characteristics and the relation to cognitive level, disease duration and disease severity in patients with Huntington’s disease

Y. Manor, D. Shpunt, N. Avniel, S. Assa, Y. Torner, A. Gad, A. Ezra, J. Knaani, A. Socher, Y. Oestriecher-Kedem, T. Gurevich (Tel Aviv, Israel)

12:00pm-1:30pm
Tau pathology in Huntington’s disease: A brief in vivo PET-imaging report

K. Giehl, K. Reetz, I. Dogan, C. Werner, J.B. Schulz, A. Drzezga, T. van Eimeren (Köln, Germany)

12:00pm-1:30pm
Temporal course of the total motor score in Huntington disease

P. Auinger, T.J. Felong, S. Gandhi, V. Abler, K. Biglan, S. Papapetropoulos, C. Venuto, R. Dorsey (Rochester, NY, USA)

12:00pm-1:30pm
Temporal course of the UHDRS chorea score in Huntington disease

T.J. Felong, P. Auinger, S. Gandhi, V. Abler, K. Biglan, S. Papapetropoulos, C. Venuto, R. Dorsey (Rochester, NY, USA)

12:00pm-1:30pm
The assessment of quality of life in patients with early and moderately advanced Huntington disease

N. Szejko, L. Milanowski, A. Gogol, Z. Jamrozik, P. Janik (Warsaw, Poland)

12:00pm-1:30pm
The effects of gait and balance training on walking economy in early and mid stage Huntington’s disease

J.L. Kubica, J. Szymura, E. Mirek, M. Filip, M. Wiecek, M. Maciejczyk, M. Rudzinska, U. Pustulka-Piwnik, J. Stozek, S. Pasiut (Krakow, Poland)

12:00pm-1:30pm
Tractography study of individuals with mutation for Huntington’s disease in symptomatic and pre-symptomatic phases

R.A. Saba, J. Yared, T. Doring, V. Borges, L.B. Barcelos, H.B. Ferraz (São Paulo, Brazil)

12:00pm-1:30pm
Verbatim patient-reported outcomes and trails making test B (TMT-B) performance in the REACH2HD trial

J.L. Purks, A. Zeymo, N.M. Shara, K.E. Anderson, I. Shoulson (Washington, DC, USA)

« View all sessions from the 20th International Congress.

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Effect of marijuana on Essential Tremor: A case report
  • Advanced Search
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley